Mapping Chinese Device Classes to Argentine Class I–IV

1. Key takeaways

The Chinese Class I/II/III categories cannot be converted directly into the Argentine Class I–IV. The two systems classify on different logic: China uses a hybrid model of catalogue plus rules, while Argentina uses a pure rule model (the 22 rules of Annex II of GMC 25/21). Any direct conversion is necessarily distorted.

The reason is structural. A catalogue assigns a class to a product type in advance, so a company in China looks up the entry and inherits the class. A pure rule model, by contrast, has no entries to look up: the class emerges from applying each rule to the specific characteristics of the device — its intended purpose, how it enters the body, how long it stays, what it touches and whether it is active. Two products with the same Chinese catalogue entry can therefore land in different Argentine classes if their use durations or contact sites differ, and that outcome is not an anomaly but the expected behavior of a rule-driven system.

The most typical misconception is equating sterile supply or a measuring function with high risk. The Argentine rules consider these factors as well, but with different weights than in China — some sterile surgical instruments registered in China as Class II may fall into Class I in Argentina, thereby qualifying for the simplest sworn-declaration pathway. The reverse also occurs: products comfortable in a Chinese category can land one class higher under the rule-by-rule Argentine analysis.

The practical takeaway is to abandon conversion as a method entirely. The Argentine classification must be rebuilt from the product’s own characteristics — intended purpose, invasiveness, duration of use, contact sites, active status — against the 22 rules, with the Chinese conclusion used at most as a conversation starter, never as the answer.

2. Legal basis

The instruments below identify the rule source for classification, the transposition instrument, and the registration pathway provisions that the classification conclusion feeds into.

3. Expert insights

Insight one: the difference in weighting concentrates on sterility and measurement. In the Chinese classification rules, sterile supply and a measuring function raise the risk class significantly; in the Argentine rule system these two factors are aggravating but not decisive, and must be combined with invasiveness, duration of use, and contact with the circulatory system or central nervous system to reach a conclusion. The same product can therefore end up one class apart in the two countries, in either direction. Treating the Chinese result as a proxy is not a shortcut but a source of systematic error.

Insight two: the four areas with the largest differences are software, implants, drug-containing components and nanomaterials — governed respectively by Rules 11, 8, 14 and 19. Software is qualified separately by Rule 11 (spanning Class I to IV); implantables are governed by Rule 8 with three up- or down-classing exceptions; drug-containing components are handled by Rule 14; and nanomaterials by Rule 19. For these four product families, the Chinese classification conclusion offers essentially no reference value, because the Argentine rules attach dedicated criteria that have no direct counterpart in the Chinese catalogue-plus-rules model.

Insight three: a lower class is not a bargain but a fork in pathway selection. A product in Class I that is non-sterile, non-measuring, non-active and listed in the relevant schedule may use the simplest sworn-declaration pathway; a Class II product uses the declaration of conformity. The classification conclusion directly determines the depth of review, so when the justification is genuinely uncertain it is safer to err conservative rather than underestimate risk to chase the fast lane.

4. Practical recommendations

1. Build a five-dimension comparison table. For intended purpose, invasiveness, duration of use, contact with the heart or central nervous or circulatory system, and active status, record the Chinese conclusion and the Argentine determination basis side by side, and mark every divergence explicitly.
2. Argue the four high-divergence families independently. Software-containing, implantable, drug-containing and nanomaterial products each require a standalone classification justification report; reasoning by analogy from the Chinese category is not acceptable.
3. Use the official consultation mechanism first. Submit the unclassified-product consultation through the TAD system and obtain an ANMAT opinion before starting document preparation, avoiding rework on an assumed class.
4. Bring the classification conclusion under change management. Any change in intended purpose, materials or structure requires the classification justification to be redone; the original conclusion cannot simply be carried forward.

The conservative instinct also has a commercial logic. A file argued one class too low will eventually be caught — at review, at import clearance or at surveillance — and the correction at that point costs far more than the extra review depth of the honest class would have cost upfront. By contrast, a file argued one class conservatively higher simply buys a deeper review and a stronger certificate: the product can still be marketed in every class it lawfully occupies, and the margin built into the classification absorbs future changes in materials or intended purpose without forcing a re-classification exercise.

5. Verification checklist

• □ The practice of direct conversion from Chinese classes has been abandoned
• □ Rule-by-rule determination against the 22 rules completed and the basis recorded
• □ Five-dimension comparison table built with divergence points marked
• □ Software, implantable, drug-containing and nanomaterial products each argued independently
• □ Borderline products submitted to the official TAD classification consultation
• □ The classification conclusion incorporated into the change-trigger mechanism

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly undertaking classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language localization of technical documentation and labels, HELENA submissions and deficiency responses, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and continuously tracks the developments of regulatory authorities worldwide; all published content follows the editorial standard of conclusions first, traceable bases and verifiable figures. For a tailored market access plan for Argentina or the MERCOSUR region covering a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.